# A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

> **NCT03677934** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 415 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** PDS Implant filled with 100 mg/mL Ranibizumab
- **DRUG:** Intravitreal Injections of 10 mg/mL Ranibizumab

## Key facts

- **NCT ID:** NCT03677934
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-12
- **Primary completion:** 2020-05-22
- **Final completion:** 2021-06-09
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03677934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03677934, "A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03677934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*